內克塔治療 NKTR 深 滬
已收盤 08-01 16:00:00 美东时间
22.96
+1.280
+5.90%
華盛通- 最 高23.00
- 今 開21.34
- 成交量 50.53万股
- 最 低 21.02
- 昨 收 21.68
- 總市值 2.85亿
- 52周最高 37.38
- 市盈率 靜 --
- 換手率 4.07%
- 52周最低 6.48
- 委 比 -96.72%
- 總股本 1240.69万
- 歷史最高 1670.40
- 量 比 0.86
- 振 幅 9.13%
- 歷史最低 6.189
- 每 手 1
- 風險率 4.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered NK cell therapies, will participate in the H.C. Wainwright "HCW@Home" Series. The event will feature a fireside chat on July 30, 2025, at 11:00 a.m. ET, and registration is available via the provided link. Nkarta is advancing allogeneic NK cell therapies for autoimmune diseases using cell engineering and genome-editing technologies. The company aims to develop accessib...
07-23 12:01
美股大行评级 | 潜在涨幅687%！ 花旗上调新氧科技目标价升至5.5美元，评级"买入"
今日重点评级关注：B. Riley证券：维持内克塔治疗"买入"评级，目标价从60美元升至85美元；Oppenheimer：维持Praxis Precision Medicine"跑赢大市"评级，目标价从97美元升至115美元
07-09 09:26
B. Riley Securities Maintains Buy on Nektar Therapeutics, Raises Price Target to $85
B. Riley Securities analyst Mayank Mamtani maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $60 to $85.
07-09 01:58
Nektar Therapeutics Prices Underwritten Public Offering Of $100M Of Shares At $23.50/Shr
Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its underwritten public offering
07-01 19:19
MSC Industrial Direct, Constellation Brands And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading higher this morning on Tuesday, some of the sto...
07-01 15:09
Nektar Therapeutics launches proposed public offering
Nektar Therapeutics (NASDAQ:NKTR) has commenced an underwritten public offering of shares of its common stock and pre-funded warrants to purchase shares of its common stock. NKTR -2.45% after hours to...
07-01 04:10
Nektar Therapeutics Announces Proposed Public Offering
SAN FRANCISCO, June 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of imm...
07-01 04:02
美股牛股 | QuantumScape涨超30%，固态电池技术取得重大突破；POET涨超17%
QuantumScape涨超30%，固态电池技术取得重大突破；POET涨超17%，公司获业内大奖，签订新协议拟扩大生产>>
06-26 19:21
美股大行评级 | 潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级；联邦快递遭多家机构下调目标价>>
06-26 08:38
Nektar Therapeutics surge continues as stock up another 25%
Nektar Therapeutics (NASDAQ:NKTR), which closed Tuesday up ~156% after its lead asset, rezpegaldesleukin, met its main goal in a mid-stage trial for atopic dermatitis, also known as eczema, is up anot...
06-26 02:14
